-
Indonesian court hears 'negligence' complaint against state over fires, haze
-
Germany factory production at highest level for 18 months
-
Rubio in Greece to urge against Western civilisation 'decline'
-
Thailand floods death toll rises to 60 since mid-September
-
Micron workers at Taiwan plant vote in favour of strike
-
US pushes Russia for information on plague reports
-
In 'The Social Reckoning,' Jeremy Allen White takes on Facebook's 'frightening' ambition
-
Myanmar leader lands in Malaysia for migrant return talks
-
Chip industry activists call for South Korea to recognise cancer cases
-
Indian central bank hikes rates for first time since 2023
-
Famine-scarred southern Madagascar braces for El Nino
-
US military on Okinawa face curfew, alcohol ban after murder case
-
How the EU regulates lobbyists
-
Fierce lobbying in EU over 'forever chemicals'
-
I.Coast refuge offers lifelong care for youngsters scorned as 'sorcerers'
-
Dodgers beat Braves and Padres avoid sweep in MLB playoffs
-
Indian central bank hikes rates for first time in more than 3 years
-
Mourning, war and elections as Israel marks October 7
-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
-
Climate champion Australia digging more coal
-
Nobel Peace Prize haunted by the 'spectre' of Trump
-
Emotion, tears as Messi retires from Argentina national team
-
Africa launches own credit agency in bid for cheaper borrowing
-
Dodgers push Braves to the brink of MLB playoff exit
-
US, China, EU: three paths to regulating AI
-
Crisis-stricken Haiti postpones elections
-
Australia's High Court rules against coal mine in landmark climate case
-
N. Korea's Kim pledges 'invariable support' in Putin birthday letter
-
Australia touts new funds for Pacific infrastructure at Fiji 'pre-COP'
-
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
-
Eva Marie Saint, Oscar winner of Hollywood classics, dies at 102
-
Emotion, tears as Messi prepares for Argentina farewell
-
Australia probes app used in cheap smart glasses over privacy fears
-
Kane eyes Ronaldo record after matching England cap mark
-
England needed to 'move on' from World Cup pain, says Tuchel
-
Spain fight back to beat Croatia, Kane adds to record for England
-
O'Neill to stay at Celtic after period of "reflection"
-
Merino double helps Spain beat Croatia, reach Nations League quarters
-
Kane marks 125th England cap with Wembley Nations League double
-
US stocks hit fresh records as oil stabilizes on rising supplies
Cannabis extract relieves chronic back pain: high-quality trial
A specially developed cannabis extract relieves chronic lower back pain, according to a clinical trial published Wednesday that experts are calling the first high-quality evidence that something in the cannabis plant can treat pain.
Lower back pain is the leading cause of disability worldwide, affecting more than half a billion people, according to the World Health Organization.
But drugs for chronic back pain are limited to common painkillers such as ibuprofen, which can have serious side effects when used long-term, or highly addictive and potentially dangerous opioids.
In recent years, an expanding cannabis industry has claimed that a range of marijuana or cannabidiol (CBD) products can help with pain, but researchers have warned that the quality of evidence actually showing this has been low.
On Wednesday, a large placebo-controlled, phase 3 clinical trial -- which is considered the gold standard for researching medical drugs -- testing a cannabis extract was published in the journal Nature Medicine.
The trial involved more than 800 people with chronic lower back pain who did not get relief from non-opioid drugs.
After 12 weeks of taking either the cannabis extract called VER-01 or a placebo, participants were asked to report their pain level on a 10-point scale.
Those taking the extract reported a 1.9-point reduction in pain, compared to 0.6 for those on the placebo.
After six months, participants taking the extract said their pain had decreased by a higher 2.9 points.
They also reported better sleep, physical function and quality of life, according to the study.
Each dose of VER-01 contains 2.5 milligrammes of THC, the main active ingredient in marijuana.
Nothing suggested that the extract was addictive or caused serious side effects, the study said. The most common side effects were short-term dizziness, sleepiness, dry mouth and some nausea -- though they decreased over time.
The study's lead author Matthias Karst, a professor of pain medicine at Hannover Medical School in Germany, told AFP that "no feelings of (being) high" were observed during the trial.
- 'As good as it gets' -
Andrew Moore, a former pain researcher at Oxford University not involved in the study, said the "terrific" trial was "about as good as it gets".
"The trial is the first that shows good quality evidence that something in the cannabis plant can be helpful for pain," he told AFP.
But Moore also urged caution about claims that the extract was not addictive, warning that in the past, such statements have later turned out to be incorrect.
Most cannabis products vary widely in potency, purity and other factors which make them difficult for doctors to safely prescribe, Karst said.
The VER-01 strain has been specifically developed to obtain approval by medical authorities and then be prescribed for chronic pain, he added.
This means the study is not "proof that all cannabis/CBD products would be helpful in the same way," Karst emphasised.
Jan Vollert, a pain researcher at Exeter University not involved in the study, also stressed the difference between this "very specific substance" and regular marijuana.
"Smoking cannabis and taking VER-01 are probably as similar as eating hazelnuts and eating Nutella: they might share a similar basis, but they just are not comparable," he said.
L.AbuTayeh--SF-PST